Work

Hydroxychloroquine usage in US patients, their experiences of tolerability and adherence, and implications for treatment: survey results from 3127 patients with SLE conducted by the Lupus Foundation of America

Year: 2019

Type: article

Abstract: The majority of patients with SLE in the USA have been prescribed hydroxychloroquine (HCQ). Given more recent guidelines, the availability of only one strength (200 mg tablets) may limit the flexibility and ability to accurately dose patients with lupus. The Lupus Foundation of America undertook a survey to assess the current landscape of HCQ tolerability and adherence.

Source: Lupus Science & Medicine

DOI: 10.1136/lupus-2019-000317

Authors: Daniel J Wallace, Karin Tse, Leslie Hanrahan, Rupert Davies, Michelle A Petri

Institutions: Cedars-Sinai Medical Center, Lupus Foundation of America, Johns Hopkins University

Language: English

Topic: Systemic Lupus Erythematosus Research

Subfield: Rheumatology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

Estimated APC paid: $2,391